Ginkgo Bioworks Slides 3.1% to $9 as Q4 Revenue Forecast Drops 15.6%
Ginkgo Bioworks shares closed at $9.00, down 3.12%, underperforming the S&P 500’s 0.1% gain and lagging the medical sector’s 0.31% rise. Analysts forecast Q4 EPS of -$1.80 and revenue of $37 million, marking a 15.6% year-over-year revenue decline.
1. Trading Performance
Shares of Ginkgo Bioworks closed at $9.00, down 3.12% for the session, trailing the S&P 500’s 0.1% gain, the Dow’s 0.07% increase and the Nasdaq’s 0.14% advance. Over the past month, shares have fallen 2.72%, underperforming the medical sector’s 0.31% rise and the S&P 500’s 1.43% decline.
2. Quarterly Forecast
Analysts project fourth-quarter earnings of -$1.80 per share and revenue of $37 million, which would represent a 15.6% drop in revenue compared to the same quarter last year and a 1.1% improvement in EPS year-over-year.
3. Annual Outlook
For the full year, consensus estimates call for EPS of -$5.94, a 42.7% improvement from the prior year’s loss, alongside revenue of $173 million, reflecting a 23.8% year-over-year decline.
4. Rank and Industry Position
Ginkgo Bioworks holds a Zacks Rank of #3 (Hold) and operates within the medical-biomedical and genetics industry, which ranks 82nd out of more than 250 industries, placing it in the top 34% based on average estimate revisions.